Galapagos disappoints again as 2 key readouts fail to generate much enthusiasm for Gilead's fading partner
The analysts still left trying to determine if Gilead’s once-big collaborator Galapagos has anything of value to offer in the pipeline were left either shaking their heads Wednesday evening or looking for some hard-to-find silver linings in the latest round of disappointing readouts.
Let’s start with GLPG3970, which Baird’s Brian Skorney has called Gilead’s next best hope of delivering some upbeat news that could offer some real value to investors.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 119,700+ biopharma pros reading Endpoints daily — and it's free.